Andrew V. Trask Ph.D.

Intellectual Property Legal Intern

Jones Day

Registered to practice before the United States Patent and Trademark Office, Dr. Trask’s work includes drafting and prosecuting U.S. and international patent applications in the pharmaceutical and biotechnology fields. He also regularly participates in patent litigation, due diligence, and opinion work. Having earned his Ph.D. from the University of Cambridge, Dr. Trask has co-authored more than a dozen peer-reviewed scientific publications and has presented at several international conferences.

Mr. Joseph Zielinski

Fellow

Novartis Pharmaceuticals

Joseph Zielinski received his MS in Pharmaceutical Science from Long Island University and his Bachelor of Science degree from Massachusetts College of Pharmacy. He has over seventeen years of formulation research and development experience in solid, non-sterile liquid, and sterile liquid dosage forms. He is the Unites States member for the Pediatric Team and The Pediatric Advisory Group at Novartis.

Dr. Michiel Van Oort

Director, Inhaled Product Development

GlaxoSmithKline, Inc

Having earned his Ph.D. from Dlahousie University in the area of polymorphism of low dimensional solids, Dr. Van Oort assesses the developability of NCEs. He identifies and utilizes alternative techniques for the generation and characterization of excipients and repirable powders. He also assesses the performance and manufacturability of new inhalation devices. He has over 100 publications, presentations and patents in the areas of solid state chemistry, in vitro characterization, particle engineering and inhalation delivery systems.

Ms. Chin Koerner

Director, U.S. Liaison Office

Novartis Pharmaceuticals

Ms. Chin Koerner currently leads the United States Liaison Office for Novartis Pharmaceuticals, where she oversees regulatory intelligence and policy work in the arenas of branded pharmaceuticals, generics, and over-the-counter products. Prior to joining Novartis, Ms. Koerner was with the FDA in different positions with oversight of pre- and post- approval issues. Her 20-year career in drug development has included a wide variety of projects from marketing to research and development.

Dr. Darin Y. Furgeson

Asst. Prof. Pharm. Sciences/Biomedical Engineering

University of Wisconsin-Madison

Dr. Furgeson earned his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry at the University of Utah in 2003. For cancer gene therapy he designed and synthesized novel linear and branched conjugates for targeting of primary tumors. By combining pharmaceutical sciences, biomolecular engineering, and polymer chemistry, his research introduces a new paradigm in drug delivery and is rapidly advancing translational options for multimodal therapy. His work has recently been recognized with an award by the Pharmaceutical Research and Manufacturers of America Foundation.

Dr. Gopi Venkatesh

Director, Research and Devlopment

Eurand USA

Dr. Gopi Venkatesh has over twenty years of pharmaceutical industry experience in the fields of drug delivery, development of novel controlled-release dosage forms and the physics of compaction of pharmaceutical materials. He holds several patents in the drug delivery area and has authored and co-authored numerous publications, abstracts, and book chapters. Dr. Venkatesh earned his Ph.D. degree from Indian Institute of Science, Bangalore, India.

Dr. Phillip Green

Director, Alternative Delivery Systems

BD Pharmaceutical Systems

Responsible for creating new opportunities for improved delivery of drugs and vaccines, Dr. Green joined BD in 1993 where he has concentrated in the area of targeted delivery of oncology agents, transdermal delivery, microneedle technology and subcutaneous infusion systems. Educated in the United Kingdom, he conducted postdoctoral research in the area of transdermal drug delivery at the University of California. In his 20 years of related pharmaceutical experience, her has been awarded several worldwide patents and has published extensively.